Palmitoyl Tripeptide-38: Physiology and What Research Reports

What Palmitoyl Tripeptide-38 Is

Palmitoyl tripeptide-38 is a synthetic lipopeptide used as a topical cosmetic ingredient. Structurally it consists of a three-amino-acid peptide sequence covalently joined to palmitic acid, a sixteen-carbon saturated fatty acid. That fatty-acid "tail" is the defining feature of the palmitoyl peptide family, which also includes palmitoyl pentapeptide-4, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. In cosmetic chemistry, palmitoylation is used because a short, water-loving peptide on its own associates poorly with the lipid-rich outer skin layer, while a lipidated version distributes more readily into an oily or emulsified vehicle.

The name follows INCI (International Nomenclature of Cosmetic Ingredients) conventions rather than pharmacological ones. The number "-38" is simply a registry identifier distinguishing one tripeptide sequence from another; it carries no information about potency, activity or safety. Readers meeting the term on an ingredient list are looking at a cosmetic-grade material, not a prescription medicine, and it is frequently marketed under trade names that group it with other peptides in a blended raw material.

Where It Comes From in the Body — and Where It Does Not

Unlike the hormones and signalling peptides catalogued elsewhere in a physiology library, palmitoyl tripeptide-38 is not produced endogenously. There is no gland, tissue or enzymatic pathway in humans that synthesises it. It is manufactured by solid-phase peptide synthesis and then acylated. What it is modelled on, however, is genuine physiology: the proteins of the dermal extracellular matrix.

The dermis is a scaffold built largely by fibroblasts. Those cells assemble type I and type III collagen fibrils, type IV and type VII collagen at the dermal–epidermal junction, elastin, fibronectin, laminins and hyaluronan. During normal turnover, matrix metalloproteinases cleave these proteins into short fragments, and some of those fragments — often called matrikines — are recognised by cells in the surrounding tissue. The design rationale behind "matrix-repair" or "pro-collagen" peptides in cosmetic science is to present a short synthetic sequence that resembles such a fragment. Whether a topically applied lipopeptide reaches viable dermis in meaningful quantity is an open question in the skin-delivery literature, and the verified clinical reports below did not address it directly.

Why the surrounding biology matters

Skin ageing is conventionally divided into intrinsic (chronological) change and extrinsic change driven mainly by ultraviolet exposure. Both converge on reduced fibroblast activity, thinner and more fragmented collagen bundles, and altered surface topography — the measurable roughness, wrinkle depth and volume that instrumentation can capture. This is why cosmetic studies of peptide-containing products so often report surface imaging endpoints rather than biochemical ones.

How Products Containing This Ingredient Class Have Been Studied

A recurring feature of the published human literature is that lipopeptides of this type were evaluated inside finished multi-ingredient formulations, not as isolated actives. That design choice limits what can be attributed to any single component.

A 2020 report in the Journal of Cosmetic Dermatology evaluated a serum containing vitamins C and E together with a matrix-repair tripeptide and reported a reduction in facial signs of ageing assessed by Primos three-dimensional skin-surface analysis and by frequently repeated auto-perception (PMID 33103342). A 2016 report in the same journal assessed a facial serum combining apple stem cell extract, a pro-collagen lipopeptide, creatine and urea and described a biorevitalising effect on skin ageing signs (PMID 26424007). A 2015 open-label clinical trial published in the Journal of Drugs in Dermatology examined a multi-ingredient anti-ageing moisturiser designed to improve the appearance of facial skin (PMID 26151786).

Measurement methods seen in these reports

• Primos analysis — an optical, projected-fringe system that builds a three-dimensional map of the skin surface so that wrinkle depth, volume and roughness can be quantified over time, used in the 2020 serum study (PMID 33103342).
• Repeated self-assessment — structured auto-perception questionnaires administered at intervals, also part of the 2020 evaluation (PMID 33103342).
• Open-label clinical design — all participants received the same product with no blinded comparator, as in the 2015 moisturiser trial (PMID 26151786).

What the Literature Reports

None of these three reports isolated a single peptide as the variable under test. In the 2016 serum study the lipopeptide sat alongside a botanical extract, creatine and urea, so improvements described there cannot be assigned to the peptide component alone (PMID 26424007). The same interpretive ceiling applies to the vitamin-containing serum, where antioxidants and the tripeptide were delivered together (PMID 33103342). This page is for educational purposes only and is not medical advice; consult a licensed physician about any skin condition, product or treatment decision.

Concentrations

The verified literature summarised here described finished cosmetic formulations rather than isolated peptide concentrations, so no use level for palmitoyl tripeptide-38 is stated on this page. Where a study did not report a figure, none is inferred.

Palmitoyl Tripeptide-38 Adverse Events: What Studies Report

Because the three verified reports evaluated complete multi-ingredient products, they do not provide adverse-event data attributable to palmitoyl tripeptide-38 as a single substance. The 2015 investigation was an open-label trial of a multi-ingredient moisturiser, a design in which tolerability observations apply to the finished product rather than to one ingredient (PMID 26151786); the same limitation applies to the 2016 serum evaluation (PMID 26424007). General dermatological principles — that topical formulations can provoke irritant or allergic contact reactions in some individuals, often driven by preservatives, fragrance or vehicle as much as by an active — are not specific to this peptide and were not tested as such in the cited work.

Why the Term Matters to Readers

Palmitoyl tripeptide-38 is a good worked example of a wider pattern in peptide literacy. The ingredient is real, the underlying matrix biology is well described, and the human data that exist are formulation-level cosmetic studies with open-label or self-assessment components rather than mechanistic trials of the molecule. Reading an ingredient list and recognising that distinction — between a plausible design rationale and a demonstrated ingredient-specific effect — is the practical skill this entry is meant to support.

Limitations of the Evidence Base

1. Multi-ingredient products dominate, so component-level attribution is not possible from the cited reports.
2. Open-label designs lack blinded comparators, as in the 2015 moisturiser trial (PMID 26151786).
3. Self-perception endpoints are subjective, even when paired with instrumental imaging as in the 2020 serum study (PMID 33103342).
4. Percutaneous delivery of lipopeptides to the dermis was not quantified in the verified reports.

References

• A serum containing vitamins C & E and a matrix-repair tripeptide reduces facial signs of aging as evidenced by Primos® analysis and frequently repeated auto-perception (Journal of Cosmetic Dermatology, 2020)
• Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs (Journal of Cosmetic Dermatology, 2016)
• An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin (Journal of Drugs in Dermatology, 2015)